Literature DB >> 32170336

Arguments against using an abbreviated or biparametric prostate MRI protocol.

Felipe B Franco1, Fiona M Fennessy2,3.   

Abstract

Currently there is a lot of interest in the use of a "biparametric" or "abbreviated" prostate MR protocol, which usually refers to removal of the dynamic contrast-enhanced (DCE) MRI, in the detection of clinically significant prostate cancer. In this article we describe the benefits of DCE as part of the PI-RADS lexicon, with particular reference to its role in PI-RADS V2 category 3 peripheral zone lesions. We also discuss the benefits of triplanar T2-weighted images, and finally discuss how a mpMRI protocol is of benefit in prostate cancer staging, in evaluating for local disease recurrence, and as a biomarker for neoadjuvant therapy response.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32170336     DOI： 10.1007/s00261-020-02474-x

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  42 in total

1.  MRI-Targeted Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-08-09       Impact factor: 91.245

2.  Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.

Authors:  H A Vargas; A M Hötker; D A Goldman; C S Moskowitz; T Gondo; K Matsumoto; B Ehdaie; S Woo; S W Fine; V E Reuter; E Sala; H Hricak
Journal:  Eur Radiol       Date:  2015-09-22       Impact factor: 5.315

3.  Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.

Authors:  Olivier Rouvière; Philippe Puech; Raphaële Renard-Penna; Michel Claudon; Catherine Roy; Florence Mège-Lechevallier; Myriam Decaussin-Petrucci; Marine Dubreuil-Chambardel; Laurent Magaud; Laurent Remontet; Alain Ruffion; Marc Colombel; Sébastien Crouzet; Anne-Marie Schott; Laurent Lemaitre; Muriel Rabilloud; Nicolas Grenier
Journal:  Lancet Oncol       Date:  2018-11-21       Impact factor: 41.316

4.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.

Authors:  Jeffrey C Weinreb; Jelle O Barentsz; Peter L Choyke; Francois Cornud; Masoom A Haider; Katarzyna J Macura; Daniel Margolis; Mitchell D Schnall; Faina Shtern; Clare M Tempany; Harriet C Thoeny; Sadna Verma
Journal:  Eur Urol       Date:  2015-10-01       Impact factor: 20.096

5.  The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.

Authors:  Olivier Wegelin; Leonie Exterkate; Marloes van der Leest; Jean A Kummer; Willem Vreuls; Peter C de Bruin; J L H Ruud Bosch; Jelle O Barentsz; Diederik M Somford; Harm H E van Melick
Journal:  Eur Urol       Date:  2018-12-03       Impact factor: 20.096

6.  PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer.

Authors:  Ji Won Seo; Su-Jin Shin; Young Taik Oh; Dae Chul Jung; Nam Hoon Cho; Young Deuk Choi; Sung Yoon Park
Journal:  AJR Am J Roentgenol       Date:  2017-04-18       Impact factor: 3.959

7.  Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen.

Authors:  Christiane K Kuhl; Robin Bruhn; Nils Krämer; Sven Nebelung; Axel Heidenreich; Simone Schrading
Journal:  Radiology       Date:  2017-07-20       Impact factor: 11.105

8.  Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.

Authors:  Francesco Porpiglia; Matteo Manfredi; Fabrizio Mele; Marco Cossu; Enrico Bollito; Andrea Veltri; Stefano Cirillo; Daniele Regge; Riccardo Faletti; Roberto Passera; Cristian Fiori; Stefano De Luca
Journal:  Eur Urol       Date:  2016-08-27       Impact factor: 20.096

9.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

10.  Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force.

Authors:  Caroline M Moore; Francesco Giganti; Peter Albertsen; Clare Allen; Chris Bangma; Alberto Briganti; Peter Carroll; Masoom Haider; Veeru Kasivisvanathan; Alex Kirkham; Laurence Klotz; Adil Ouzzane; Anwar R Padhani; Valeria Panebianco; Peter Pinto; Philippe Puech; Antti Rannikko; Raphaele Renard-Penna; Karim Touijer; Baris Turkbey; Heinrik van Poppel; Riccardo Valdagni; Jochen Walz; Ivo Schoots
Journal:  Eur Urol       Date:  2016-06-24       Impact factor: 20.096
View more
  1 in total

Review 1.  Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer.

Authors:  Alexander P Cole; Bjoern J Langbein; Francesco Giganti; Fiona M Fennessy; Clare M Tempany; Mark Emberton
Journal:  Br J Radiol       Date:  2021-12-16       Impact factor: 3.039
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.